New York, NY, May 26, 2026 (GLOBE NEWSWIRE) -- In a challenge brought by Eli Lilly and Company, BBB National Programs’ National Advertising Division recommended that Noom, Inc. modify or discontinue its Microdose GLP-1RX Program “A Smaller Dose. A SmarterStart” claim.
Lilly and Noom compete in the weight-loss market. Lilly markets tirzepatide-based prescription medications Mounjaro® and Zepbound®. Noom is a weight-loss platform that offers GLP-1 medications in conjunction with its behavior-change program.
At issue for the National Advertising Division (NAD) was whether the claim “Noom GLP-1Rx Program A Smaller Dose. A Smarter Start. Microdose GLP-1Rx Starts at $119*.” constituted non-actionable puffery or, in context, conveyed an objective health-related message requiring substantiation.
NAD determined that one message reasonably conveyed by the challenged claim is that Noom’s product is “smarter” due to its “smaller” dose, and that the smaller dosage provides a measurable, health-related benefit, which requires substantiation.
NAD found that Noom did not provide adequate support for the message that Noom’s specific lower-dose approach provides a measurable health-related benefit that makes it a “smarter start.”
Accordingly, NAD recommended that Noom discontinue the claim “NOOM GLP-1Rx PROGRAM A Smaller Dose. A Smarter Start. MICRODOSE GLP-1Rx STARTS AT $119*” or modify its advertising to avoid conveying the message that the lower dose of medication provided by the Noom Microdose GLP-1Rx Program itself provides a measurable, health-related benefit that makes it a smarter or better way to begin treatment.
NAD noted that nothing in its decision precludes Noom from promoting its program or the benefits of its behavior-modification tools as a smarter start, provided the advertising does not tie that message to unsupported dosage-related benefits.
During the inquiry, Noom informed NAD that it was permanently discontinuing all other challenged express claims, including dosing, efficacy, side effect, and other health-related claims. Based on Noom’s representation that the discontinued claims were being permanently discontinued, NAD did not review them on their merits and will treat the permanently discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
In its advertiser statement, Noom stated that while it “disagrees with NAD’s conclusion,” it “voluntarily agrees to comply with NAD’s recommendation.”
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Pursuant to NAD/NARB Procedures, this release may not be used for promotional purposes.
About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.
About the National Advertising Division: The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and creating fair competition for business.
Name: Jennifer Rosenberg Email: jrosenberg@bbbnp.org Job Title: Media Relations
